Abstract Core binding factor acute myelogenous leukemia (CBF-AML). characterized by the presence of either t(8;21) (q22;q22) or inv(16) (p13q22)/t(16;16). is considered good-risk AML in the context of cytarabine based intensive chemotherapy. Still. https://yeswellneses.shop/product-category/paper-products/